pivanex
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2003 (NCT00073385)
Timeline
Indications
Mechanism of action
- Histone deacetylaseINHIBITOR
Histone deacetylase inhibitor
- Histone deacetylase 1 (HDAC1) ↗
- Histone deacetylase 3 (HDAC3) ↗
- Histone deacetylase 6 (HDAC6) ↗
- Histone deacetylase 2 (HDAC2) ↗
- Histone deacetylase 5 (HDAC5) ↗
- Histone deacetylase 7 (HDAC7) ↗
- Histone deacetylase 8 (HDAC8) ↗
- Histone deacetylase 11 (HDAC11) ↗
- Histone deacetylase 4 (HDAC4) ↗
- Histone deacetylase 9 (HDAC9) ↗
- Histone deacetylase 10 (HDAC10) ↗
- Histone deacetylase 8
- Histone deacetylase 10
- Histone deacetylase 2
- Histone deacetylase 3
- Histone deacetylase 4
- Histone deacetylase 6
- Histone deacetylase 9
- Histone deacetylase 11
- Histone deacetylase 5
- Histone deacetylase 7
- Histone deacetylase 1
- Histone deacetylase (HDAC1 and HDAC2)
- Histone deacetylase 1/3/5/8
- Histone deacetylase 1/2/3/6
- Histone deacetylase 1/2/3
- Histone deacetylase 1/8
- Histone deacetylase 1/6
- Class 1 histone deacetylase
- Histone deacetylase 6/3
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- an 9
- an-9
- an-9
- an-9
- pivaloyloxymethylbutyrate
- pivaloyloxymethylbutyrate
- pivaloyloxymethyl butyrate
- pivaloyloxymethyl butyrate
- pivalyloxymethyl butyrate
- pivanex
- pivanex
- pivanex
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00083473 | Phase 2 | May 1, 2004 | Titan Pharmaceuticals |
| NCT00087477 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2004 | Titan Pharmaceuticals |
| NCT00073385 | Phase 2 | Sep 1, 2003 | Titan Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Titan Pharmaceuticals | For profit | 3 | 3 | 1 | 2003 |
1 organizations
Page 1 / 1